MedTrace Logo

A Retrospective Real-World Study Based on RATIONALE-307

NCT07478809 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2026-03-27

No results posted yet for this study

Summary

The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07478809 on ClinicalTrials.gov